The soluble urokinase plasminogen activator receptor (suPAR) is increased earlier than IL-1β, and plasma suPAR ≥ 6 ng/ml have been used in the SAVE-MORE study to guide the use of anakinra in hospitalized patients without respiratory failure defined by the use of high-flow oxygen (HFO), non-invasive ventilation (NIV) or IMV (21). This evidence concerns the gene PLAUR and respiratory failure.